Immune Checkpoint Biopharma Therapies sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Immune Checkpoint Biopharma Therapies
1.1 - About Immune Checkpoint Biopharma Therapies sector
Companies in the Immune Checkpoint Biopharma Therapies category discover, develop, and commercialize monoclonal antibody drugs that block inhibitory signaling (e.g., PD‑1/PD‑L1, CTLA‑4) to restore anti‑tumor immunity. They offer clinically validated and next‑generation immunotherapies, combination regimens, and lifecycle management across multiple solid and hematologic cancers, delivering scalable biologics manufacturing, global regulatory support, and market access capabilities to expand patient reach and treatment effectiveness.
Offerings typically include monoclonal antibodies against PD‑1, PD‑L1, and CTLA‑4, with pipelines advancing LAG‑3, TIGIT, and TIM‑3 targets. Vendors engineer bispecific checkpoint antibodies and optimize Fc domains and glycosylation to fine‑tune effector functions. They provide subcutaneous and long‑acting formulations, GMP biologics manufacturing, end‑to‑end clinical development and regulatory submissions, and biomarker programs such as PD‑L1 IHC and tumor mutational burden assays to enable patient stratification and combination‑therapy design.
These companies serve oncology providers and hospital systems administering infused biologics, biopharma partners pursuing combination immuno‑oncology trials, and payers/HTA organizations evaluating value and access. Outcomes include expanded treatment choices across tumor types, improved response rates and survival in defined biomarker segments, accelerated clinical timelines through established development infrastructure, and broader market access via label extensions, real‑world evidence generation, and optimized dosing that reduces infusion chair time.
2. Buyers in the Immune Checkpoint Biopharma Therapies sector
2.1 Top strategic acquirers of Immune Checkpoint Biopharma Therapies companies
Alector
- Description: Provider of biotechnology research and clinical-stage therapies targeting neurodegenerative diseases, developing antibody-based and protein-engineering candidates that remove toxic proteins, replace deficient proteins and restore immune and neuronal function, leveraging genetically validated targets and its proprietary Alector Brain Carrier blood-brain barrier technology.
- Key Products:
- Therapeutic Candidate Pipeline: Pipeline of first- and best-in-class therapeutic candidates that remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function in neurodegenerative disorders
- Alector Brain Carrier (ABC) technology: Proprietary ABC technology for blood-brain barrier transport, enabling efficient delivery of antibodies and engineered proteins directly to brain tissue for enhanced therapeutic efficacy
- Protein Engineering & Antibody Discovery Expertise: In-house protein engineering and antibody discovery capabilities generate novel, highly specific molecules that target neurodegenerative disease pathways, accelerating development of transformative immuno-neurology therapies
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Immune Checkpoint Biopharma Therapies sector
M&A buyer group 1: Cancer Immunotherapy
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Immune Checkpoint Biopharma Therapies sector
3.1 - Buyout funds in the Immune Checkpoint Biopharma Therapies sector
2.2 - Strategic buyer groups for Immune Checkpoint Biopharma Therapies sector
4 - Top valuation comps for Immune Checkpoint Biopharma Therapies companies
4.2 - Public trading comparable groups for Immune Checkpoint Biopharma Therapies sector
Valuation benchmark group 1: Monoclonal Antibody Drug Developers
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.